Last $3.22 USD
Change Today +0.04 / 1.26%
Volume 54.9K
ANTH On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

anthera pharmaceuticals inc (ANTH) Snapshot

Open
$3.15
Previous Close
$3.18
Day High
$3.26
Day Low
$3.12
52 Week High
07/19/13 - $4.60
52 Week Low
05/7/14 - $2.54
Market Cap
67.3M
Average Volume 10 Days
100.8K
EPS TTM
$-1.60
Shares Outstanding
20.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ANTHERA PHARMACEUTICALS INC (ANTH)

anthera pharmaceuticals inc (ANTH) Related Bloomberg News

View More Bloomberg News

anthera pharmaceuticals inc (ANTH) Related Businessweek News

No Related Businessweek News Found

anthera pharmaceuticals inc (ANTH) Details

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing products to treat diseases associated with inflammation and autoimmune diseases. It is developing blisibimod, a Phase III product candidate that targets elevated levels of B-cell activating factor associated with various B-cell mediated autoimmune diseases, including systemic lupus erythematosus, IgA nephropathy, lupus nephritis, multiple myeloma, vasculitis, idiopathic thrombocytopenia purpura, and others. The company was founded in 2004 and is headquartered in Hayward, California.

25 Employees
Last Reported Date: 03/28/14
Founded in 2004

anthera pharmaceuticals inc (ANTH) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $577.3K
Senior Vice President of Finance & Administra...
Total Annual Compensation: $224.6K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $350.0K
Chief Technology Officer and Senior Vice Pres...
Total Annual Compensation: $340.0K
Compensation as of Fiscal Year 2013.

anthera pharmaceuticals inc (ANTH) Key Developments

Anthera Pharmaceuticals Announces Board Changes

Anthera Pharmaceuticals, Inc. announced the appointment of Brian R. Mueller to its Board of Directors and as Chairman of the Audit Committee of the Board of Directors. Mr. Brian R. Mueller currently serves as Group Vice President, Corporate Controller and Chief Accounting Officer of BioMarin Pharmaceutical Inc. Concurrent with the appointment of Mr. Brian R. Mueller, Mr. Daniel Spiegelman resigned from Anthera's Board of Directors and Chairman of the Audit Committee of the Board of Directors. Mr. Daniel Spiegelman joined the Anthera Board of Directors in 2010.

Anthera Pharmaceuticals, Inc. Announces Board Changes

Anthera Pharmaceuticals, Inc. announced the appointment of Dr. Philip Sager, MD, FACC, FAHA, FHRS, to its Board of Directors. Dr. Sager is a Fellow of the American College of Cardiology, a Fellow of the American Heart Association and a Fellow of the Heart Rhythm Society. Dr. Sager has served as a Consulting Professor of Medicine at the Stanford University School of Medicine since 2013, a Full Voting Member of the United States Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee since 2011, a private pharmaceutical, device and diagnostics consultant since 2010 and Member of the Scientific Programs Committee, the Scientific Oversight Committee, and the Executive Committee of the Cardiac Safety Research Consortium since 2006, serving as Chair of the Scientific Programs Committee and Scientific Oversight Committee at various times. Effective at the company's annual general meeting held on June 10, 2014 Dr. Bogdan Dziurzynski has retired from the company's board of directors. Dr. Dziurzynski joined the company's Board of Directors in 2012.

Anthera Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Anthera Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company announced loss from operations of $7,609,000 compared to $6,901,000 for the same period a year ago. Net loss was $7,916,000 compared to $7,580,000 for the same period a year ago. Net loss per share, basic and diluted were $0.39 compared to $0.49 for the same period a year ago. Its net loss widened as research and development costs increased related to its Phase 3 clinical lupus study.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANTH:US $3.22 USD +0.04

ANTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ANTH.
View Industry Companies
 

Industry Analysis

ANTH

Industry Average

Valuation ANTH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 6.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANTHERA PHARMACEUTICALS INC, please visit www.anthera.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.